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Thymomas are relatively uncommon malignancies and their low incidence has contrib-uted to the uncertainty regarding their optimal management. The prognosis of these 
epithelial tumors is dictated primarily by the stage of the disease.1,2 Although the histo-
logical classification has been shown by many to be of prognostic significance, its repro-
ducibility has been a subject of controversy.3 Histologic features are described using the 
World Health Organization (WHO) classification (Table 1), which assesses morphology, 
lymphocytic infiltration, and architectural features such as palisading or sheet-like growth. 
Stage is established using the Masaoka system (Table 2), based on capsular integrity, the 
degree of invasion, and the presence of metastases. By and large, more aggressive histo-
logical forms of thymic malignancies are more often diagnosed at later stages. Most cases 
of thymoma are characterized by an indolent course and the standard therapeutic strategy 
is surgical resection, when feasible. However, there is little consensus regarding postop-
erative management.4 Adjuvant radiotherapy has been advocated in nonradically resected 
cases, stage III and IV radically resected thymomas, and thymic carcinomas, but its use is 
controversial in earlier stages of the disease and in less aggressive histological types. The 
value of adjuvant radiation and chemotherapy has been a contentious point and there are no 
randomized data on which to base treatment strategies. After stage, the ability to perform 
a radical resection (R0) is the most important prognostic factor.5,6 Radical resection is, in 
general, less common with more aggressive histological forms.
In the accompanying article, Gao et al.7 describe 188 consecutive patients with WHO 
type B3 thymoma at their institution. B3 thymomas were previously called well-differenti-
ated thymic carcinomas8 and they represent a distinct, aggressive subset of thymic tumors, 
which is often considered together with thymic carcinomas. The biology is poorly under-
stood, but the genetic abnormalities in B3 and C (carcinomas) seem to be rather similar.9 
In the accompanying study of the 188 patients, 177 were treated with curative intent: 159 
underwent thymectomy (105 were R0) and 18 had a debulking surgery followed by radia-
tion. The treatments were far from uniform, though most patients received multimodality 
therapy. Radiation was delivered to 126 of the 177 patients, primarily in the adjuvant setting. 
Systemic treatment was less common, with only 35 patients receiving chemotherapy, again, 
primarily as an adjuvant therapy. The outcomes reported are consistent with prior studies. In 
a report of 241 resected cases, Maggi et al.10 reported 10-year overall survival of 87%, 60%, 
64%, and 40% for patients with stage I, II, III, and IVA thymoma, respectively. Comparable 
outcomes were reported in the 307-patient cohort described by Regnard et al.5 (80%, 78%, 
47%, 30%). In the accompanying article, the 10-year overall survival is 65% but there a 
striking dichotomy between stage I and II (89%, 86%) and stage III and IV (61%, 42%) 
disease. As expected, the presence of residual disease was associated with inferior outcomes 
but even within these subgroups, stage still carried prognostic value. Among patients who 
received an R0 resection or achieved a complete response to radiation, the freedom from 
recurrence rate at 10 years was excellent for stage I and II (100%, 94%) but dropped to 
56% for stage III. For patients with residual disease (R1 or R2 resection or partial response 
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to radiation), the outcomes were worse, with a 5-year time to 
progression of 41% for stage III and 24% for stage IV.
This study certainly has limitations, and the authors are 
careful not to overstate their findings. The lack of uniform 
treatment is common in retrospective analyses and there are 
many possible confounders that could have influenced the 
decisions regarding adjuvant therapy. In addition, the descrip-
tion of adjuvant therapy would have benefitted from analysis 
by stage. The study of one specific histologic subtype (here, 
B3) is of great value as it eliminates one aspect of heteroge-
neity found in most other studies. There is no clear descrip-
tion, however, of central pathology verification, which will 
be essential to future studies, as reproducibly classifying 
thymoma remains a clinical challenge. Despite these limita-
tions, this large analysis of patients with B3 thymoma does 
contribute to our collective understanding of the disease. First, 
this study further supports the utility of the Masaoka staging 
system within B3 thymoma as a powerful prognostic variable. 
Furthermore, this report underscores the need for structured, 
prospective studies of adjuvant therapy. On the basis of the 
findings reported here, it would be clinically meaningful 
and more likely for a study to determine any possible ben-
efit to postoperative adjuvant therapy in a cohort enriched for 
patients with Masaoka stage III and IV, WHO type B3 thy-
moma. An international phase III trial is being planned to 
assess the benefit of neoadjuvant chemotherapy and adjuvant 
radiation therapy. This study will have several arms and will 
include a randomization for induction chemotherapy versus 
none and adjuvant radiation versus none. It is only through 
the support of multicenter, well-structured studies that we can 
advance the treatment paradigm for rare malignancies such as 
B3 thymoma.
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TABLE 1.  WHO Classification6
Type Description
A A tumor composed of a population of neoplastic thymic 
epithelial cells having spindle/oval shape, lacking nuclear 
atypia, and accompanied by few or no non-neoplastic 
lymphocytes.
AB A tumor in which foci having the features of type A thymoma 
are admixed with foci rich in lymphocytes.
B1 A tumor that resembles the normal functional thymus in that it 
combines large expanses having an appearance practically 
indistinguishable from normal thymic cortex with areas 
resembling thymic medulla.
B2 A tumor in which the neoplastic epithelial component appears 
as scattered plump cells with vesicular nuclei and distinct 
nucleoli among a heavy population of lymphocytes. 
Perivascular spaces are common and sometimes very 
prominent. A perivascular arrangement of tumor cells 
resulting in a palisading effect may be seen.
B3 A type of thymoma predominantly composed of epithelial 
cells having a round or polygonal shape and exhibiting no or 
mild atypia. They are admixed with a minor component of 
lymphocytes, resulting in a sheet-like growth of the neoplastic 
epithelial cells.
C A thymic tumor exhibiting clear-cut cytologic atypia and a 
set of cytoarchitectural features no longer specific to the 
thymus, but rather analogous to those seen in carcinomas of 
other organs. Type C thymomas lack immature lymphocytes; 
whatever lymphocytes may be present are mature and usually 
admixed with plasma cells.
TABLE 2.  Masaoka Clinical Staging System11
Stage Description
I Tumor remains completely 
encapsulated
II A Microscopic transcapsular 
invasion
B Macroscopic invasion into 
surrounding fatty tissue 
or grossly adherent 
to (but not through) 
mediastinal pleura or 
pericardium
III Macroscopic invasion 
into neighboring organs 
(i.e., pericardium, great 
vessels, lung)
A Without invasion of great 
vessels
B With invasion of great 
vessels
IV A Pleural or pericardial 
dissemination
B Lymphogenous or 
hematogenous metastasis
